319 related articles for article (PubMed ID: 32826320)
1. Noninvasive Evaluation of CD20 Expression Using
Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
[TBL] [Abstract][Full Text] [Related]
2.
Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626
[TBL] [Abstract][Full Text] [Related]
3. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
5. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
7. Preparation and preliminary bioevaluation studies of
Suman SK; Kameswaran M; Pandey U; Sarma HD; Dash A
J Labelled Comp Radiopharm; 2019 Oct; 62(12):850-859. PubMed ID: 31461549
[TBL] [Abstract][Full Text] [Related]
8.
Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
[TBL] [Abstract][Full Text] [Related]
9. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
10. Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.
Lin X; Zhu H; Luo Z; Hong Y; Zhang H; Liu X; Ding H; Tian H; Yang Z
Mol Imaging Biol; 2014 Dec; 16(6):877-87. PubMed ID: 24833041
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
12. ImmunoPET of Malignant and Normal B Cells with
Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
[No Abstract] [Full Text] [Related]
13. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
15. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using
Shi D; Zhang Y; Xu Z; Si Z; Cheng Y; Cheng D; Liu G
Mol Imaging; 2022; 2022():3748315. PubMed ID: 35903247
[TBL] [Abstract][Full Text] [Related]
17.
Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ
J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of
Shi D; Fu W; Tan H; Lin Q; Shi H; Cheng D
Mol Pharm; 2024 Jan; 21(1):303-312. PubMed ID: 38109713
[TBL] [Abstract][Full Text] [Related]
19. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
20. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
